COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up
A Tajbakhsh, SM Gheibi Hayat… - Expert review of anti …, 2021 - Taylor & Francis
ABSTRACT Introduction Coronavirus disease 2019 (COVID-19) has the characteristics of
high transmission, diverse clinical manifestations, and a long incubation period. In addition …
high transmission, diverse clinical manifestations, and a long incubation period. In addition …
Association between renin-angiotensin-aldosterone system inhibitors and clinical outcomes in patients with COVID-19: a systematic review and meta-analysis
Importance The chronic receipt of angiotensin-converting enzyme inhibitors (ACEIs) and
angiotensin receptor blockers (ARBs) has been assumed to exacerbate complications …
angiotensin receptor blockers (ARBs) has been assumed to exacerbate complications …
Infectious Diseases Society of America Guidelines on the treatment and management of patients with coronavirus disease 2019 (COVID-19)
Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …
Elastase and exacerbation of neutrophil innate immunity are involved in multi‐visceral manifestations of COVID‐19
JL Guéant, RM Guéant‐Rodriguez, J Fromonot… - Allergy, 2021 - Wiley Online Library
Background Many arguments suggest that neutrophils could play a prominent role in COVID‐
19. However, the role of key components of neutrophil innate immunity in severe forms of …
19. However, the role of key components of neutrophil innate immunity in severe forms of …
[HTML][HTML] A meta-analysis on the risk factors adjusted association between cardiovascular disease and COVID-19 severity
J Xu, W Xiao, X Liang, L Shi, P Zhang, Y Wang… - BMC public health, 2021 - Springer
Background Cardiovascular disease (CVD), one of the most common comorbidities of
coronavirus disease 2019 (COVID-19), has been suspected to be associated with adverse …
coronavirus disease 2019 (COVID-19), has been suspected to be associated with adverse …
[HTML][HTML] Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients
F Yan, F Huang, J Xu, P Yang, Y Qin, J Lv, S Zhang… - Cell Discovery, 2020 - nature.com
The novel coronavirus (CoV) severe acute respiratory syndrome (SARS)-CoV-2 outbreak
began at the end of 2019 in Wuhan, China, and has spread to over 200 countries. In this …
began at the end of 2019 in Wuhan, China, and has spread to over 200 countries. In this …
[HTML][HTML] Lack of association of antihypertensive drugs with the risk and severity of COVID-19: a meta-analysis
L Ren, S Yu, W Xu, JL Overton, N Chiamvimonvat… - Journal of …, 2021 - Elsevier
Background The association of antihypertensive drugs with the risk and severity of COVID-
19 remains unknown. Methods and Results We systematically searched PubMed …
19 remains unknown. Methods and Results We systematically searched PubMed …
[HTML][HTML] Cell deaths: Involvement in the pathogenesis and intervention therapy of COVID-19
X Li, Z Zhang, Z Wang… - Signal transduction and …, 2022 - nature.com
The current pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has dramatically influenced …
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has dramatically influenced …
A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor
The recent emergence of coronavirus disease-2019 (COVID-19) as a global pandemic has
prompted scientists to address an urgent need for defining mechanisms of disease …
prompted scientists to address an urgent need for defining mechanisms of disease …
[HTML][HTML] Mortality and disease severity among COVID-19 patients receiving renin-angiotensin system inhibitors: a systematic review and meta-analysis
Introduction The use of renin-angiotensin system (RAS) inhibitors, including angiotensin-
converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), was …
converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), was …